Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

被引：86

作者：

Yang, Yunpeng ^{[1
]}

Pan, Jianji ^{[2
]}

Wang, Hui ^{[3
]}

Zhao, Yuanyuan ^{[1
]}

Qu, Shenhong ^{[4
]}

Chen, Nianyong ^{[5
,6
]}

Chen, Xiaozhong ^{[7
]}

Sun, Yan ^{[8
]}

He, Xiaohui ^{[9
]}

Hu, Chaosu ^{[10
]}

Lin, Lizhu ^{[11
]}

Yu, Qitao ^{[12
]}

Wang, Siyang ^{[13
]}

Wang, Guihua ^{[14
]}

Lei, Feng ^{[15
]}

Wen, Jiyu ^{[16
]}

Yang, Kunyu ^{[17
]}

Lin, Zhixiong ^{[18
]}

Guo, Ye ^{[19
]}

Chen, Shaoqing ^{[20
]}

Huang, Xiaoming ^{[21
]}

Wu, Yanjie ^{[22
]}

Liang, Liang ^{[23
]}

Chen, Chenqi ^{[22
]}

Bai, Fan ^{[22
]}

Ma, Xiaopeng ^{[24
]}

Zhang, Yun ^{[23
]}

Leaw, Shiangjiin ^{[22
]}

Zhang, Li ^{[1
]}

Fang, Wenfeng ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Med Oncol Sun Yat, State Key Lab Oncol South China,Canc Ctr,Guangdong, 16th Floor,2 Bldg,Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China

[2] Fujian Canc Hosp, Dept Head & Neck Radiat Oncol, 420 Fuma Rd, Fuzhou 350014, Fujian, Peoples R China

[3] Hunan Canc Hosp, Thorac Radiotherapy Dept 1, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China

[4] Guangxi Acad Med Sci, Peoples Hosp Guangxi Zhuang Autonomous Reg, Canc Res Inst, Otolaryngol Dept, 6 Tao Yuan Rd, Nanning 530021, Guangxi, Peoples R China

[5] Sichuan Univ, West China Hosp, Canc Ctr, Dept Head & Neck Oncol, 37 Guoxuexiang, Chengdu 610041, Sichuan, Peoples R China

[6] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, 37 Guoxuexiang, Chengdu 610041, Sichuan, Peoples R China

[7] Zhejiang Canc Hosp, Dept Head & Neck Radiotherapy, 38 Guangji Rd, Hangzhou 310022, Zhejiang, Peoples R China

[8] Beijing Canc Hosp, Radiotherapy Dept, 52 Fucheng Rd, Beijing 100142, Peoples R China

[9] Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, 17 Panjiayuannanli, Beijing 100021, Peoples R China

[10] Fudan Univ, Shanghai Canc Ctr, Dept Radiat, 270 Dongan Rd, Shanghai 200032, Peoples R China

[11] Guangzhou Tradit Chinese Med Univ, Affiliated Hosp 1, Dept Oncol, 16 Airport Rd, Guangzhou 510405, Guangdong, Peoples R China

[12] Guangxi Med Univ, Affiliated Canc Hosp, Dept Med Oncol Resp, 71 Hedi Rd, Nanning 530021, Guangxi, Peoples R China

[13] Sun Yat Sen Univ, Affiliated Hosp 5, Head & Neck Oncol Sect 1, 52 Meihua East Rd, Zhuhai 519000, Peoples R China

[14] Changsha Cent Hosp, Dept Oncol, 161 Shaoshan South Rd, Changsha 410004, Hunan, Peoples R China

[15] Peoples Hosp Zhongshan City, Head & Neck Radiotherapy Dept, 2 Sunwen East Rd, Zhongshan 528403, Guangdong, Peoples R China

[16] Guangdong Med Univ, Affiliated Hosp, Canc Ctr, Nasopharyngeal Canc Dis Ctr, 57 South Renmin Rd, Zhanjiang 524000, Guangdong, Peoples R China

[17] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China

[18] Shantou Univ, Canc Hosp, Med Coll, Dept Radiat, 7 Raoping Rd, Shantou 515031, Guangdong, Peoples R China

[19] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Oncol, 1800 Yuntai Rd, Shanghai 200123, Peoples R China

[20] Nanchang Univ, Affiliated Hosp 1, Dept Oncol, 17 Yongwaizheng St, Nanchang 330006, Jiangxi, Peoples R China

[21] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Otolaryngol Head & Neck Surg, 107 Yan Jiang West Rd, Guangzhou 510120, Guangdong, Peoples R China

[22] BeiGene Shanghai Co Ltd, Jing Kerry Ctr, Clin Dev, 20-F,Tower 3,1228 Middle Yanan Rd, Shanghai 200040, Peoples R China

[23] BeiGene Beijing Co Ltd, Clin Biomarker Sci & CDx Dev, 6 Jianguomenwai Ave,SK Tower,36th Floor, Beijing 100022, Peoples R China

[24] BeiGene Beijing Co Ltd, Bioinformat, 30 Sci Pk Rd,Zhongguancun Life Sci Pk, Beijing 102206, Peoples R China

来源：

CANCER CELL | 2023年 / 41卷 / 06期

关键词：

biomarker; clinical trial; double-blinded; gene expression profiling; immunotherapy; nasopharyngeal carcinoma; PD-1; inhibitor; randomized; tislelizumab;

D O I：

10.1016/j.ccell.2023.04.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC patients to tislelizumab or placebo every 3 weeks (Q3W), plus chemotherapy (Q3W for 4-6 cycles). At interim analysis, progression-free survival (PFS) was significantly longer with tislelizumab-chemotherapy versus placebo -chemotherapy (hazard ratio: 0.52; 95% confidence interval: 0.38, 0.73; p < 0.0001). PFS benefit for tislelizumabchemotherapy versus placebo-chemotherapy was observed regardless of programmed death-ligand 1 expression. PFS after next line of treatment and overall survival showed favorable trends for tislelizumab-chemotherapy versus placebo-chemotherapy. The safety profile was similar between arms. Gene expression profiling (GEP) identified immunologically "hot"tumors, and showed an activated dendritic cell (DC) signature was associated with tislelizumab-chemotherapy PFS benefit. Our results support that tislelizumab-chemotherapy should be considered as first-line treatment for R/M NPC, and GEP and activated DC signature results may help identify patients who might benefit most from immunochemotherapy treatment.

引用

页码：1061 / +

页数：17

共 50 条

[21] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
Xu, Jianming
Kato, Ken
Raymond, Eric
Hubner, Richard A.
Shu, Yongqian
Pan, Yueyin
Park, Sook Ryun
Ping, Lu
Jiang, Yi
Zhang, Jingdong
Wu, Xiaohong
Yao, Yuanhu
Shen, Lin
Kojima, Takashi
Gotovkin, Evgeny
Ishihara, Ryu
Wyrwicz, Lucjan
Van Cutsem, Eric
Jimenez-Fonseca, Paula
Lin, Chen -Yuan
Wang, Lei
Shi, Jingwen
Li, Liyun
Yoon, Harry H.
LANCET ONCOLOGY, 2023, 24 (05): : 483 - 495
[22] Phase II trial of first-line capecitabine plus cisplatin in patients with advanced/metastatic nasopharyngeal cancer (NPC)
Chua, D.
Ng, W.
Yiu, H.
Seetalarom, K.
Kurnianda, J.
Sze, W.
Krishnan, G.
Shotelersuk, K.
Hong, R.
Forster, G.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[23] Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer A Phase 3 Randomized Clinical Trial
Wang, Jie
Lu, Shun
Yu, Xinmin
Hu, Yanping
Sun, Yuping
Wang, Zhijie
Zhao, Jun
Yu, Yan
Hu, Chunhong
Yang, Kunyu
Feng, Guosheng
Ying, Kejing
Zhuang, Wu
Zhou, Jianying
Wu, Jingxun
Leaw, Shiang Jiin
Zhang, Jing
Lin, Xiao
Liang, Liang
Yang, Nong
JAMA ONCOLOGY, 2021, 7 (05) : 709 - 717
[24] Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
Shu, Yongqian
Pan, Yueyin
Lu, Ping
Jiang, Yi
Zhang, Jingdong
Wu, Xiaohong
Yao, Yuanhu
Shen, Lin
Ba, Yi
He, Zhiyong
Bai, Yuxian
Chen, Jianhua
Yu, Guohua
Peng, Yanyan
Wu, Hongqian
Wang, Lei
Li, Liyun
Xu, Jianming
CANCER RESEARCH, 2023, 83 (08)
[25] Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial (vol 27, pg 1536, 2021)
Mai, Hai-Qiang
Chen, Qiu-Yan
Chen, Dongping
Hu, Chaosu
Yang, Kunyu
Wen, Jiyu
Li, Jingao
Shi, Ying-Rui
Jin, Feng
Xu, Ruilian
Pan, Jianji
Qu, Shenhong
Li, Ping
Hu, Chunhong
Liu, Yi-Chun
Jiang, Yi
He, Xia
Wang, Hung-Ming
Lim, Wan-Teck
Liao, Wangjun
He, Xiaohui
Chen, Xiaozhong
Liu, Zhigang
Yuan, Xianglin
Li, Qi
Lin, Xiaoyan
Jing, Shanghua
Chen, Yanju
Lu, Yin
Hsieh, Ching-Yun
Yang, Muh-Hwa
Yen, Chia-Jui
Samol, Jens
Feng, Hui
Yao, Sheng
Keegan, Patricia
Xu, Rui-Hua
NATURE MEDICINE, 2022, 28 (01) : 214 - 214
[26] PHASE II TRIAL OF FIRST-LINE CAPECITABINE PLUS OXALIPLATIN IN PATIENTS WITH METASTATIC NASOPHARYNGEAL CARCINOMA
Chua, D.
Ng, W. T.
Ng, W. Y.
Lui, C. Y.
Li, V.
Cheng, A.
ANNALS OF ONCOLOGY, 2010, 21 : 324 - 324
[27] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
Cappuzzo, F
Mazzoni, F
Gennari, A
Donati, S
Salvadori, B
Orlandini, C
Cetto, GL
Molino, A
Galligioni, E
Mansutti, M
Tumolo, S
Lucentini, A
Valduga, F
Bartolini, S
Crinò, L
Conte, PF
BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 31 - 35
[28] Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer
F Cappuzzo
F Mazzoni
A Gennari
S Donati
B Salvadori
C Orlandini
G L Cetto
A Molino
E Galligioni
M Mansutti
S Tumolo
A Lucentini
F Valduga
S Bartolini
L Crinò
P F Conte
British Journal of Cancer, 2004, 90 : 31 - 35
[29] A multicenter phase II trial of tumor treating fields plus chemotherapy for first-line treatment of gastric adenocarcinoma
Li, Jin
Yeo, Winnie
Lam, Ka-On
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[30] Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study
Ren, Xiang
Tian, Yiqun
Wang, Zhixian
Wang, Jing
Li, Xing
Yin, Yisheng
Chen, Ruibao
Zhan, Ying
Zeng, Xiaoyong
BMC UROLOGY, 2022, 22 (01)

← 1 2 3 4 5 →